Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Regeneron Pharmaceuticals | INDUSTRY |
Not provided
Not provided
Not provided
To assess the efficacy of intravitreal (IVT) administration of aflibercept with two different approaches of Treat and Extend dosing regimens in Japanese subjects with neovascular (wet) Age-related Macular Degeneration (wAMD) .
To assess the safety of IVT administration of aflibercept with two different approaches of Treat and Extend dosing regimen in Japanese subjects with wAMD for up to 2 years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 2 Weeks adjustment | Experimental | Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96. |
|
| 4 Weeks adjustment | Experimental | Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Drug | Aflibercept 2mg is intravitreally injected. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change From Baseline in BCVA at Week 52 | Visual functions of the study eye (at every visit) and the fellow eye were assessed, according to the ETDRS protocol as described in detail in the operation manual. A higher score represents better functioning. | Baseline and Week 52 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Who Maintained Vision at Week 52 | A participant was classified as maintaining vision if the participant had lost fewer than 15 letters in the ETDRS letter score compared to baseline. | Week 52 |
| Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ichinomiya | Aichi-ken | 491-8551 | Japan | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35503499 | Result | Okada AA, Takahashi K, Ohji M, Moon SC, Machewitz T, Sasaki K; ALTAIR Study Investigators. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup. Adv Ther. 2022 Jun;39(6):2984-2998. doi: 10.1007/s12325-022-02162-w. Epub 2022 May 3. | |
| 34283294 |
Not provided
Not provided
288 participants were enrolled and 255 entered run-in phase. 8 were randomization failures. 247 participants were randomized (2 Weeks [2W] adjustment group: 124; 4 Weeks [4W] adjustment group: 123) at Week 16. All 247 participant:s were treated and 227 participants (111 in the 2W adjustment, 116 in the 4W adjustment) completed Week 52 treatment.
Study was conducted in Japan between 19 December 2014 (first participant first visit) and 08 November 2017 (last participant last visit).
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 2 Weeks Adjustment | Participants received Aflibercept Intravitreal (IVT) injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline and Week 52 |
| Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52 | Baseline and week 52 |
| Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52 | A participant was classified as without fluid if "Evidence of new or persistent fluid" on OCT was "No". | Week 52 |
| Nagoya |
| Aichi-ken |
| 457-8510 |
| Japan |
| Nagoya | Aichi-ken | 467-8602 | Japan |
| Toyoake | Aichi-ken | 470-1192 | Japan |
| Asahi | Chiba | 289-2511 | Japan |
| Sakura | Chiba | 285-8741 | Japan |
| Kōriyama | Fukushima | 963-8052 | Japan |
| Kure | Hiroshima | 737-0029 | Japan |
| Sapporo | Hokkaido | 001-0016 | Japan |
| Sapporo | Hokkaido | 060-0010 | Japan |
| Sapporo | Hokkaido | 065-0031 | Japan |
| Kobe | Hyōgo | 650-0047 | Japan |
| Inashiki-gun | Ibaraki | 300-0395 | Japan |
| Mito | Ibaraki | 310-0845 | Japan |
| Morioka | Iwate | 020-8505 | Japan |
| Yokohama | Kanagawa | 232-0024 | Japan |
| Nankoku | Kochi | 783-8505 | Japan |
| Miyakonojō | Miyazaki | 885-0051 | Japan |
| Iida | Nagano | 395-8502 | Japan |
| Matsumoto | Nagano | 390-8621 | Japan |
| Hirakata | Osaka | 573-1191 | Japan |
| Moriguchi | Osaka | 570-8507 | Japan |
| Sayama | Osaka | 589-8511 | Japan |
| Takatsuki | Osaka | 569-1096 | Japan |
| Ōtsu | Shiga | 520-2192 | Japan |
| Chiyoda-ku | Tokyo | 101-8309 | Japan |
| Chuoku | Tokyo | 104-8560 | Japan |
| Hachiōji | Tokyo | 193-0998 | Japan |
| Mitaka | Tokyo | 181-8611 | Japan |
| Shinjuku-ku | Tokyo | 160-0023 | Japan |
| Shinjuku-ku | Tokyo | 162-8666 | Japan |
| Taito-ku | Tokyo | 111-0051 | Japan |
| Shimonoseki | Yamaguchi | 750-0061 | Japan |
| Ube | Yamaguchi | 755-8505 | Japan |
| Chūō | Yamanashi | 409-3898 | Japan |
| Fukuoka | 812-8582 | Japan |
| Fukuoka | 814-0180 | Japan |
| Miyazaki | 889-1692 | Japan |
| Okayama | 700-8558 | Japan |
| Osaka | 533-0024 | Japan |
| Osaka | 545-8586 | Japan |
| Ohji M, Okada AA, Sasaki K, Moon SC, Machewitz T, Takahashi K; ALTAIR Investigators. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study. Graefes Arch Clin Exp Ophthalmol. 2021 Dec;259(12):3637-3647. doi: 10.1007/s00417-021-05293-y. Epub 2021 Jul 20. |
| 32016788 | Derived | Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020 Mar;37(3):1173-1187. doi: 10.1007/s12325-020-01236-x. Epub 2020 Feb 3. |
| FG001 | 4 Weeks Adjustment | Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96. |
| FG002 | Randomization Failure | Participants entered run-in phase but discontinued the study before randomization after receiving at least one injection. |
| Treated |
|
| Randomized |
|
| BCVA Post-randomization Assessment |
|
| COMPLETED | Completed Treatment (Week 96) |
|
| NOT COMPLETED |
|
|
Safety analysis set (SAF): included all subjects who received any study drug
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 2 Weeks Adjustment | Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96. |
| BG001 | 4 Weeks Adjustment | Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96. |
| BG002 | Randomization Failure | Participants entered run-in phase but discontinued the study before randomization after receiving at least one injection. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||
| Best-corrected visual acuity (BCVA) | Visual functions of the study eye at Screening screening visit were assessed, according to the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol as described in detail in the operation manual. | Mean | Standard Deviation | letters |
| |||||||||
| Central Retinal Thickness | Participants in SAF with data available for central retinal thickness | Mean | Standard Deviation | μm |
| |||||||||
| Choroidal neovascularization | Count of Participants | Participants |
| |||||||||||
| Typical age-related macular degeneration | Count of Participants | Participants |
| |||||||||||
| Polypoidal Choroidal Vasculopathy | Count of Participants | Participants |
| |||||||||||
| Retinal Angiomatous Proliferation | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Change From Baseline in BCVA at Week 52 | Visual functions of the study eye (at every visit) and the fellow eye were assessed, according to the ETDRS protocol as described in detail in the operation manual. A higher score represents better functioning. | The outcome measure is analyzed based on full analysis set (FAS) including all randomized participants who received any study drug after randomization and had a baseline and at least one BCVA assessment after Week 16 (i.e. post randomization). The FAS was analyzed as randomized. | Posted | Mean | Standard Deviation | letters | Baseline and Week 52 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Maintained Vision at Week 52 | A participant was classified as maintaining vision if the participant had lost fewer than 15 letters in the ETDRS letter score compared to baseline. | The outcome measure is analyzed based on full analysis set (FAS) including all randomized participants who received any study drug after randomization and had a baseline and at least one BCVA assessment after Week 16 (i.e. post randomization). The FAS was analyzed as randomized. | Posted | Number | 95% Confidence Interval | percentage of participants | Week 52 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52 | The outcome measure is analyzed based on full analysis set (FAS) including all randomized participants who received any study drug after randomization and had a baseline and at least one BCVA assessment after Week 16 (i.e. post randomization). The FAS was analyzed as randomized. | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline and Week 52 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52 | The outcome measure is analyzed based on full analysis set (FAS) with number of subjects evaluable for this specific end point. | Posted | Mean | 95% Confidence Interval | μm | Baseline and week 52 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52 | A participant was classified as without fluid if "Evidence of new or persistent fluid" on OCT was "No". | The outcome measure is analyzed based on full analysis set (FAS) including all randomized participants who received any study drug after randomization and had a baseline and at least one BCVA assessment after Week 16 (i.e. post randomization). The FAS was analyzed as randomized. | Posted | Number | 95% Confidence Interval | Percentage of participants | Week 52 |
|
Up to 96 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 2 Weeks Adjustment | Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96. | 19 | 124 | 49 | 124 | ||
| EG001 | 4 Weeks Adjustment | Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96. | 20 | 123 | 61 | 123 | ||
| EG002 | Randomization Failure | Participants entered run-in phase but discontinued the study before randomization after receiving at least one injection. | 3 | 7 | 4 | 7 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute myocardial infarction | Cardiac disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Angina pectoris | Cardiac disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Angina unstable | Cardiac disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Coronary artery stenosis | Cardiac disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Tachycardia | Cardiac disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Sinus node dysfunction | Cardiac disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Cataract | Eye disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Age-related macular degeneration | Eye disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Gastric polyps | Gastrointestinal disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Ileus | Gastrointestinal disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Gastric mucosal lesion | Gastrointestinal disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Vascular stent stenosis | General disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Cholangitis | Hepatobiliary disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Cholecystitis | Hepatobiliary disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Cholecystitis acute | Hepatobiliary disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Hepatic failure | Hepatobiliary disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA 20.1 | Non-systematic Assessment |
| |
| Diverticulitis | Infections and infestations | MedDRA 20.1 | Non-systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 20.1 | Non-systematic Assessment |
| |
| Vestibular neuronitis | Infections and infestations | MedDRA 20.1 | Non-systematic Assessment |
| |
| Facial bones fracture | Injury, poisoning and procedural complications | MedDRA 20.1 | Non-systematic Assessment |
| |
| Femur fracture | Injury, poisoning and procedural complications | MedDRA 20.1 | Non-systematic Assessment |
| |
| Snake bite | Injury, poisoning and procedural complications | MedDRA 20.1 | Non-systematic Assessment |
| |
| Spinal fracture | Injury, poisoning and procedural complications | MedDRA 20.1 | Non-systematic Assessment |
| |
| Spinal column stenosis | Musculoskeletal and connective tissue disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Bile duct cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 20.1 | Non-systematic Assessment |
| |
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 20.1 | Non-systematic Assessment |
| |
| Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 20.1 | Non-systematic Assessment |
| |
| Laryngeal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 20.1 | Non-systematic Assessment |
| |
| Lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 20.1 | Non-systematic Assessment |
| |
| Squamous cell carcinoma of lung | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 20.1 | Non-systematic Assessment |
| |
| Colon adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 20.1 | Non-systematic Assessment |
| |
| Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 20.1 | Non-systematic Assessment |
| |
| Gingival cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 20.1 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Haemorrhage intracranial | Nervous system disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Hepatic encephalopathy | Nervous system disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Spinal epidural haematoma | Nervous system disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA 20.1 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Atrial fibrillation | Cardiac disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Vertigo | Ear and labyrinth disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Cataract | Eye disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Conjunctival haemorrhage | Eye disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Dry eye | Eye disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Retinal pigment epithelial tear | Eye disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Age-related macular degeneration | Eye disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Gastric ulcer | Gastrointestinal disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Toothache | Gastrointestinal disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Large intestine polyp | Gastrointestinal disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Oedema peripheral | General disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Cholecystitis acute | Hepatobiliary disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Conjunctivitis | Infections and infestations | MedDRA 20.1 | Non-systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA 20.1 | Non-systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 20.1 | Non-systematic Assessment |
| |
| Contusion | Injury, poisoning and procedural complications | MedDRA 20.1 | Non-systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Joint swelling | Musculoskeletal and connective tissue disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA 20.1 | Non-systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 20.1 | Non-systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Therapeutic Area Head | Bayer | (+) 1-888-8422937 | clinical-trials-contact@bayer.com |
| ID | Term |
|---|---|
| D057135 | Wet Macular Degeneration |
| D008268 | Macular Degeneration |
| ID | Term |
|---|---|
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C533178 | aflibercept |
Not provided
Not provided
Not provided
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|